What Is It, and Why Does It Matter? Sogroya (somapacitan-beco) is a long-acting form of human growth hormone. You take it as a shot under the skin (subcutaneous) one time each week. It attaches to ...

A new study published in The Journal of Clinical Endocrinology & Metabolism showed that once-weekly somapacitan, a ...

PLAINSBORO, N.J., Feb. 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® ...

Please provide your email address to receive an email when new articles are posted on . Somapacitan-beco is a once-weekly growth hormone injection. New indications expand treatment options for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BOSTON — An investigational long-acting form of recombinant human growth hormone (rhGH) given twice a month has achieved efficacy and safety at 2 years, new data show. The novel long-acting ...

Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...

Adult height serves as a comprehensive biological proxy for early-life conditions and long-term well-being. Despite the well-established genetic basis of height, current research predominantly employs ...

The REAL8 trial showed that after 52 weeks, once-weekly Sogroya ® (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin ® (somatropin) in children born small for ...